Chronic CD4+ T-cell activation and depletion in human immunodeficiency virus type 1 infection: type I interferon-mediated disruption of T-cell dynamics.

PubWeight™: 1.77‹?› | Rank: Top 3%

🔗 View Article (PMC 2258719)

Published in J Virol on December 12, 2007

Authors

Ahmad R Sedaghat1, Jennifer German, Tanya M Teslovich, Joseph Cofrancesco, Chunfa C Jie, C Conover Talbot, Robert F Siliciano

Author Affiliations

1: Johns Hopkins University School of Medicine, Department of Medicine, 879 BRB, 733 N. Broadway, Baltimore, Maryland 21205, USA.

Articles citing this

Global genomic analysis reveals rapid control of a robust innate response in SIV-infected sooty mangabeys. J Clin Invest (2009) 3.55

Natural SIV hosts: showing AIDS the door. Science (2012) 2.03

T cell dynamics and the response to HAART in a cohort of HIV-1-infected elite suppressors. Clin Infect Dis (2009) 1.94

Genome-wide mRNA expression correlates of viral control in CD4+ T-cells from HIV-1-infected individuals. PLoS Pathog (2010) 1.90

Rapid influx and death of plasmacytoid dendritic cells in lymph nodes mediate depletion in acute simian immunodeficiency virus infection. PLoS Pathog (2009) 1.66

Comparative transcriptomics of extreme phenotypes of human HIV-1 infection and SIV infection in sooty mangabey and rhesus macaque. J Clin Invest (2011) 1.61

Immunopathogenesis of asymptomatic chronic HIV Infection: the calm before the storm. Curr Opin HIV AIDS (2009) 1.39

Interferon-alpha drives monocyte gene expression in chronic unsuppressed HIV-1 infection. AIDS (2010) 1.34

Persistent immune activation in chronic HIV infection: do any interventions work? AIDS (2013) 1.24

HMGA1 drives stem cell, inflammatory pathway, and cell cycle progression genes during lymphoid tumorigenesis. BMC Genomics (2011) 1.19

Interferon-α is the primary plasma type-I IFN in HIV-1 infection and correlates with immune activation and disease markers. PLoS One (2013) 1.19

HIV-1 Vpu antagonism of tetherin inhibits antibody-dependent cellular cytotoxic responses by natural killer cells. J Virol (2014) 1.19

Interferon-alpha regulates the dynamic balance between human activated regulatory and effector T cells: implications for antiviral and autoimmune responses. Immunology (2010) 1.18

Plasmacytoid dendritic cells accumulate and secrete interferon alpha in lymph nodes of HIV-1 patients. PLoS One (2010) 1.15

Programmed death-1 is a marker for abnormal distribution of naive/memory T cell subsets in HIV-1 infection. J Immunol (2013) 1.14

HIV-1 and interferons: who's interfering with whom? Nat Rev Microbiol (2015) 1.14

Elevated interleukin 8 and T-helper 1 and T-helper 17 cytokine levels prior to antiretroviral therapy in participants who developed immune reconstitution inflammatory syndrome during ACTG A5164. J Infect Dis (2012) 1.12

Generalized immune activation and innate immune responses in simian immunodeficiency virus infection. Curr Opin HIV AIDS (2011) 1.10

Desensitization to type I interferon in HIV-1 infection correlates with markers of immune activation and disease progression. Blood (2009) 1.10

Immune activation and collateral damage in AIDS pathogenesis. Front Immunol (2013) 1.08

Interferon-alpha administration enhances CD8+ T cell activation in HIV infection. PLoS One (2012) 1.06

Host genetics and HIV-1: the final phase? PLoS Pathog (2010) 1.06

Blockade of interferon Beta, but not interferon alpha, signaling controls persistent viral infection. Cell Host Microbe (2015) 1.01

Blocking TLR7- and TLR9-mediated IFN-α production by plasmacytoid dendritic cells does not diminish immune activation in early SIV infection. PLoS Pathog (2013) 0.99

Innate immune responses and rapid control of inflammation in African green monkeys treated or not with interferon-alpha during primary SIVagm infection. PLoS Pathog (2014) 0.98

The role of cytokines in the pathogenesis and treatment of HIV infection. Cytokine Growth Factor Rev (2012) 0.93

Innate antiviral response: role in HIV-1 infection. Viruses (2011) 0.93

In acute pathogenic SIV infection plasmacytoid dendritic cells are depleted from blood and lymph nodes despite mobilization. J Med Primatol (2010) 0.92

Plasmacytoid dendritic cells in HIV infection. Adv Exp Med Biol (2013) 0.90

Interferon-alpha, immune activation and immune dysfunction in treated HIV infection. Clin Transl Immunology (2014) 0.89

Sterol regulatory element-binding protein 2 couples HIV-1 transcription to cholesterol homeostasis and T cell activation. J Virol (2011) 0.88

Systemic dendritic cell mobilization associated with administration of FLT3 ligand to SIV- and SHIV-infected macaques. AIDS Res Hum Retroviruses (2009) 0.87

Major depletion of plasmacytoid dendritic cells in HIV-2 infection, an attenuated form of HIV disease. PLoS Pathog (2009) 0.86

Type I interferon contributes to CD4+ T cell depletion induced by infection with HIV-1 in the human thymus. J Virol (2011) 0.86

Systems biology of natural simian immunodeficiency virus infections. Curr Opin HIV AIDS (2012) 0.85

Harnessing Mechanistic Knowledge on Beneficial Versus Deleterious IFN-I Effects to Design Innovative Immunotherapies Targeting Cytokine Activity to Specific Cell Types. Front Immunol (2014) 0.85

Discordance between peripheral and colonic markers of inflammation during suppressive ART. J Acquir Immune Defic Syndr (2014) 0.85

Dendritic cells in progression and pathology of HIV infection. Trends Immunol (2013) 0.84

Virus-encoded TLR ligands reveal divergent functional responses of mononuclear phagocytes in pathogenic simian immunodeficiency virus infection. J Immunol (2013) 0.84

Functional networking of human divergently paired genes (DPGs). PLoS One (2013) 0.83

Tumor-necrosis factor impairs CD4(+) T cell-mediated immunological control in chronic viral infection. Nat Immunol (2016) 0.83

Dissecting the role of dendritic cells in simian immunodeficiency virus infection and AIDS. Immunol Res (2011) 0.83

HIV-1 host interactions: integration of large-scale datasets. F1000 Biol Rep (2009) 0.82

Impact of antigen specificity on CD4+ T cell activation in chronic HIV-1 infection. BMC Infect Dis (2013) 0.81

HIV-1 Tat Protein Activates both the MyD88 and TRIF Pathways To Induce Tumor Necrosis Factor Alpha and Interleukin-10 in Human Monocytes. J Virol (2016) 0.81

Cellular Antiviral Factors that Target Particle Infectivity of HIV-1. Curr HIV Res (2016) 0.80

Intact type I Interferon production and IRF7 function in sooty mangabeys. PLoS Pathog (2013) 0.80

The HIV-1 gp120/V3 modifies the response of uninfected CD4 T cells to antigen presentation: mapping of the specific transcriptional signature. J Transl Med (2011) 0.80

Blocking type I interferon signaling enhances T cell recovery and reduces HIV-1 reservoirs. J Clin Invest (2016) 0.78

In Vivo and in Vitro Proteome Analysis of Human Immunodeficiency Virus (HIV)-1-infected, Human CD4(+) T Cells. Mol Cell Proteomics (2017) 0.78

Modulation of type I interferon-associated viral sensing during acute simian immunodeficiency virus infection in African green monkeys. J Virol (2014) 0.78

Comparison of transcriptional profiles between CD4+ and CD8+ T cells in HIV type 1-infected patients. AIDS Res Hum Retroviruses (2013) 0.78

Type I and Type II Interferon Coordinately Regulate Suppressive Dendritic Cell Fate and Function during Viral Persistence. PLoS Pathog (2016) 0.77

The simian immunodeficiency virus targets central cell cycle functions through transcriptional repression in vivo. PLoS One (2011) 0.76

Antiretroviral therapy, interferon sensitivity, and virologic setpoint in human immunodeficiency virus/hepatitis C virus coinfected patients. Hepatology (2014) 0.75

Confident gene activity prediction based on single histone modification H2BK5ac in human cell lines. BMC Bioinformatics (2017) 0.75

Type-I Interferon Responses: From Friend to Foe in the Battle against Chronic Viral Infection. Front Immunol (2016) 0.75

Differential partial activation phenotype and production of tumour necrosis factor-α by conventional dendritic cells in response to lipopolysaccharide in HIV+ viraemic subjects and HIV+ controllers. Clin Exp Immunol (2014) 0.75

Identification of miRNA-mRNA crosstalk in CD4(+) T cells during HIV-1 infection by integrating transcriptome analyses. J Transl Med (2017) 0.75

Accelerated disease progression and robust innate host response in aged SIVmac239-infected Chinese rhesus macaques is associated with enhanced immunosenescence. Sci Rep (2017) 0.75

A curated transcriptome dataset collection to investigate the immunobiology of HIV infection. F1000Res (2016) 0.75

Insufficient natural killer cell responses against retroviruses: how to improve NK cell killing of retrovirus-infected cells. Retrovirology (2016) 0.75

IFN-ε protects primary macrophages against HIV infection. JCI Insight (2016) 0.75

Interferon-Inducible CD169/Siglec1 Attenuates Anti-HIV-1 Effects of IFN-α. J Virol (2017) 0.75

Articles cited by this

Gene ontology: tool for the unification of biology. The Gene Ontology Consortium. Nat Genet (2000) 336.52

Linear models and empirical bayes methods for assessing differential expression in microarray experiments. Stat Appl Genet Mol Biol (2004) 101.91

Exploration, normalization, and summaries of high density oligonucleotide array probe level data. Biostatistics (2003) 100.88

A comparison of normalization methods for high density oligonucleotide array data based on variance and bias. Bioinformatics (2003) 82.89

Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature (1995) 34.97

TRANSFAC: transcriptional regulation, from patterns to profiles. Nucleic Acids Res (2003) 29.26

Systematic determination of genetic network architecture. Nat Genet (1999) 25.45

Microbial translocation is a cause of systemic immune activation in chronic HIV infection. Nat Med (2006) 24.38

Quantification of latent tissue reservoirs and total body viral load in HIV-1 infection. Nature (1997) 15.49

CD4+ T cell depletion during all stages of HIV disease occurs predominantly in the gastrointestinal tract. J Exp Med (2004) 13.55

Identification of genes differentially regulated by interferon alpha, beta, or gamma using oligonucleotide arrays. Proc Natl Acad Sci U S A (1998) 13.39

Gastrointestinal tract as a major site of CD4+ T cell depletion and viral replication in SIV infection. Science (1998) 12.81

MATCH: A tool for searching transcription factor binding sites in DNA sequences. Nucleic Acids Res (2003) 11.82

Transcriptional regulation by the phosphorylation-dependent factor CREB. Nat Rev Mol Cell Biol (2001) 10.69

A TH1-->TH2 switch is a critical step in the etiology of HIV infection. Immunol Today (1993) 10.43

Shorter survival in advanced human immunodeficiency virus type 1 infection is more closely associated with T lymphocyte activation than with plasma virus burden or virus chemokine coreceptor usage. J Infect Dis (1999) 9.81

Primary HIV-1 infection is associated with preferential depletion of CD4+ T lymphocytes from effector sites in the gastrointestinal tract. J Exp Med (2004) 9.11

Asymmetric T lymphocyte division in the initiation of adaptive immune responses. Science (2007) 7.64

Apoptosis occurs predominantly in bystander cells and not in productively infected cells of HIV- and SIV-infected lymph nodes. Nat Med (1995) 6.50

Nonpathogenic SIV infection of sooty mangabeys is characterized by limited bystander immunopathology despite chronic high-level viremia. Immunity (2003) 6.19

Similarities and differences in CD4+ and CD8+ effector and memory T cell generation. Nat Immunol (2003) 5.90

T cell dynamics in HIV-1 infection. Annu Rev Immunol (2001) 5.29

CD4+ T-cell depletion in HIV infection: are we closer to understanding the cause? Nat Med (2002) 5.18

Integration of interferon-alpha/beta signalling to p53 responses in tumour suppression and antiviral defence. Nature (2003) 4.80

Toward an understanding of the functional complexity of the E2F and retinoblastoma families. Cell Growth Differ (1998) 4.38

The dynamics of CD4+ T-cell depletion in HIV disease. Nature (2001) 4.37

Distinct lineages of T(H)1 cells have differential capacities for memory cell generation in vivo. Nat Immunol (2002) 4.00

Type I interferons keep activated T cells alive. J Exp Med (1999) 3.98

CD4 T cell depletion is linked directly to immune activation in the pathogenesis of HIV-1 and HIV-2 but only indirectly to the viral load. J Immunol (2002) 3.85

Apoptosis and interferons: role of interferon-stimulated genes as mediators of apoptosis. Apoptosis (2003) 3.73

T-cell division in human immunodeficiency virus (HIV)-1 infection is mainly due to immune activation: a longitudinal analysis in patients before and during highly active antiretroviral therapy (HAART). Blood (2000) 3.59

Transmission of signals from the T lymphocyte antigen receptor to the genes responsible for cell proliferation and immune function: the missing link. Annu Rev Immunol (1990) 3.55

Progressive CD4+ central memory T cell decline results in CD4+ effector memory insufficiency and overt disease in chronic SIV infection. J Exp Med (2007) 3.45

Rapid turnover of T lymphocytes in SIV-infected rhesus macaques. Science (1998) 3.39

T cell depletion in HIV-1 infection: how CD4+ T cells go out of stock. Nat Immunol (2000) 3.33

Gastrointestinal T lymphocytes retain high potential for cytokine responses but have severe CD4(+) T-cell depletion at all stages of simian immunodeficiency virus infection compared to peripheral lymphocytes. J Virol (1998) 3.30

Identification of dynamically distinct subpopulations of T lymphocytes that are differentially affected by HIV. J Exp Med (2001) 3.05

Naturally-occurring CD4+CD25+ immunoregulatory T cells: central players in the arena of peripheral tolerance. Semin Immunol (2004) 2.88

Mining for regulatory programs in the cancer transcriptome. Nat Genet (2005) 2.88

Collagen deposition in HIV-1 infected lymphatic tissues and T cell homeostasis. J Clin Invest (2002) 2.82

Functional genomic analysis of the response of HIV-1-infected lymphatic tissue to antiretroviral therapy. J Infect Dis (2004) 2.68

New concepts in the immunopathogenesis of HIV infection. Annu Rev Immunol (1995) 2.61

Cyclin A in cell cycle control and cancer. Cell Mol Life Sci (2002) 2.49

Analysis of apoptosis in lymph nodes of HIV-infected persons. Intensity of apoptosis correlates with the general state of activation of the lymphoid tissue and not with stage of disease or viral burden. J Immunol (1995) 2.42

Accelerated immune senescence and HIV-1 infection. Exp Gerontol (2007) 2.41

Cutting Edge: The direct action of type I IFN on CD4 T cells is critical for sustaining clonal expansion in response to a viral but not a bacterial infection. J Immunol (2006) 2.33

Subpopulations of long-lived and short-lived T cells in advanced HIV-1 infection. J Clin Invest (2003) 2.33

Abnormal activation and cytokine spectra in lymph nodes of people chronically infected with HIV-1. Blood (2007) 2.21

CD4+ T-cell death induced by infectious and noninfectious HIV-1: role of type 1 interferon-dependent, TRAIL/DR5-mediated apoptosis. Blood (2005) 2.21

Regulation of interleukin 2 receptor expression: effects of phorbol diester, phospholipase C, and reexposure to lectin or antigen. J Immunol (1984) 2.20

Loss of mucosal CD4 lymphocytes is an early feature of HIV infection. Clin Exp Immunol (1993) 2.17

IL-27 and IFN-alpha signal via Stat1 and Stat3 and induce T-Bet and IL-12Rbeta2 in naive T cells. J Interferon Cytokine Res (2003) 2.08

Viral dynamics in HIV-1 infection. Cell (1998) 2.08

Distinct transcriptional profiles in ex vivo CD4+ and CD8+ T cells are established early in human immunodeficiency virus type 1 infection and are characterized by a chronic interferon response as well as extensive transcriptional changes in CD8+ T cells. J Virol (2007) 2.03

Apoptosis as an HIV strategy to escape immune attack. Nat Rev Immunol (2003) 2.02

Decreased survival of B cells of HIV-viremic patients mediated by altered expression of receptors of the TNF superfamily. J Exp Med (2004) 2.00

Interferon-alpha activates multiple STAT proteins and upregulates proliferation-associated IL-2Ralpha, c-myc, and pim-1 genes in human T cells. Blood (1999) 1.97

Regulation of TNF-related apoptosis-inducing ligand on primary CD4+ T cells by HIV-1: role of type I IFN-producing plasmacytoid dendritic cells. Proc Natl Acad Sci U S A (2005) 1.97

Diverse host responses and outcomes following simian immunodeficiency virus SIVmac239 infection in sooty mangabeys and rhesus macaques. J Virol (1998) 1.94

Increased rates of CD4(+) and CD8(+) T lymphocyte turnover in simian immunodeficiency virus-infected macaques. Proc Natl Acad Sci U S A (1998) 1.88

Parallel loss of myeloid and plasmacytoid dendritic cells from blood and lymphoid tissue in simian AIDS. J Immunol (2007) 1.86

In vivo dynamics of T cell activation, proliferation, and death in HIV-1 infection: why are CD4+ but not CD8+ T cells depleted? Proc Natl Acad Sci U S A (2002) 1.82

Lymphatic tissue fibrosis is associated with reduced numbers of naive CD4+ T cells in human immunodeficiency virus type 1 infection. Clin Vaccine Immunol (2006) 1.80

Interferon alpha and Tat involvement in the immunosuppression of uninfected T cells and C-C chemokine decline in AIDS. Proc Natl Acad Sci U S A (1998) 1.68

The role of Stat4 in species-specific regulation of Th cell development by type I IFNs. J Immunol (1998) 1.65

Interferon-producing cells fail to induce proliferation of naive T cells but can promote expansion and T helper 1 differentiation of antigen-experienced unpolarized T cells. J Exp Med (2003) 1.54

Peripheral S-phase T cells in HIV disease have a central memory phenotype and rarely have evidence of recent T cell receptor engagement. J Infect Dis (2005) 1.47

Growth imbalance and altered expression of cyclins B1, A, E, and D3 in MOLT-4 cells synchronized in the cell cycle by inhibitors of DNA replication. Cell Growth Differ (1995) 1.41

Immune activation correlates better than HIV plasma viral load with CD4 T-cell decline during HIV infection. J Acquir Immune Defic Syndr (2001) 1.39

Low immune activation despite high levels of pathogenic human immunodeficiency virus type 1 results in long-term asymptomatic disease. J Virol (2007) 1.35

Decreased survival of B cells of HIV-viremic patients mediated by altered expression of receptors of the TNF superfamily. J Exp Med (2004) 1.18

Perturbations of cell cycle control in T cells contribute to the different outcomes of simian immunodeficiency virus infection in rhesus macaques and sooty mangabeys. J Virol (2006) 1.17

Anti-HIV state but not apoptosis depends on IFN signature in CD4+ T cells. J Immunol (2006) 1.11

Understanding the slow depletion of memory CD4+ T cells in HIV infection. PLoS Med (2007) 1.08

Activation-induced CD4+ T cell death in HIV-positive individuals correlates with Fas susceptibility, CD4+ T cell count, and HIV plasma viral copy number. AIDS Res Hum Retroviruses (1999) 1.04

Effects of interferon-alpha on cytokine profile, T cell receptor repertoire and peptide reactivity of human allergen-specific T cells. Eur J Immunol (1996) 1.02

Direct HIV cytopathicity cannot account for CD4 decline in AIDS in the presence of homeostasis: a worst-case dynamic analysis. J Acquir Immune Defic Syndr Hum Retrovirol (1998) 1.02

IFN-gamma and IFN-alpha posttranscriptionally down-regulate the IL-4-induced IL-4 receptor gene expression. J Immunol (2000) 0.99

Expression of human pim family genes is selectively up-regulated by cytokines promoting T helper type 1, but not T helper type 2, cell differentiation. Immunology (2005) 0.95

Mechanisms of transcriptional activation of cAMP-responsive element-binding protein CREB. Mol Cell Biochem (2000) 0.93

Abnormal intracellular kinetics of cell-cycle-dependent proteins in lymphocytes from patients infected with human immunodeficiency virus: a novel biologic link between immune activation, accelerated T-cell turnover, and high levels of apoptosis. Blood (2001) 0.87

Early correction of cell cycle perturbations predicts the immunological response to therapy in HIV-infected patients. AIDS (2004) 0.85

In vivo regulation of the entry into M-phase: initial activation and nuclear translocation of cyclin B/Cdc2. Prog Cell Cycle Res (1997) 0.84

IFN-alpha 2b reduces IL-2 production and IL-2 receptor function in primary CD4+ T cells. J Immunol (2000) 0.83

Articles by these authors

Association analyses of 249,796 individuals reveal 18 new loci associated with body mass index. Nat Genet (2010) 23.08

LocusZoom: regional visualization of genome-wide association scan results. Bioinformatics (2010) 13.54

Large-scale association analysis provides insights into the genetic architecture and pathophysiology of type 2 diabetes. Nat Genet (2012) 11.09

Long-term follow-up studies confirm the stability of the latent reservoir for HIV-1 in resting CD4+ T cells. Nat Med (2003) 9.75

Meta-analysis identifies 13 new loci associated with waist-hip ratio and reveals sexual dimorphism in the genetic basis of fat distribution. Nat Genet (2010) 7.94

Replication-competent noninduced proviruses in the latent reservoir increase barrier to HIV-1 cure. Cell (2013) 6.47

Stimulation of HIV-1-specific cytolytic T lymphocytes facilitates elimination of latent viral reservoir after virus reactivation. Immunity (2012) 6.29

The metabochip, a custom genotyping array for genetic studies of metabolic, cardiovascular, and anthropometric traits. PLoS Genet (2012) 6.15

Comparative genomics identifies a flagellar and basal body proteome that includes the BBS5 human disease gene. Cell (2004) 6.10

Gene map of the extended human MHC. Nat Rev Genet (2004) 6.01

Basal body dysfunction is a likely cause of pleiotropic Bardet-Biedl syndrome. Nature (2003) 5.96

Residual human immunodeficiency virus type 1 viremia in some patients on antiretroviral therapy is dominated by a small number of invariant clones rarely found in circulating CD4+ T cells. J Virol (2006) 5.41

A common genetic variant in the neurexin superfamily member CNTNAP2 increases familial risk of autism. Am J Hum Genet (2008) 5.28

The challenge of viral reservoirs in HIV-1 infection. Annu Rev Med (2002) 4.73

Large-scale association analyses identify new loci influencing glycemic traits and provide insight into the underlying biological pathways. Nat Genet (2012) 4.73

Maintenance of viral suppression in HIV-1-infected HLA-B*57+ elite suppressors despite CTL escape mutations. J Exp Med (2006) 4.62

Effect of the 2011 vs 2003 duty hour regulation-compliant models on sleep duration, trainee education, and continuity of patient care among internal medicine house staff: a randomized trial. JAMA Intern Med (2013) 4.49

Isolation and characterization of replication-competent human immunodeficiency virus type 1 from a subset of elite suppressors. J Virol (2006) 4.27

Intermittent HIV-1 viremia (Blips) and drug resistance in patients receiving HAART. JAMA (2005) 4.24

Genome-wide trans-ancestry meta-analysis provides insight into the genetic architecture of type 2 diabetes susceptibility. Nat Genet (2014) 4.13

Comparative analysis of measures of viral reservoirs in HIV-1 eradication studies. PLoS Pathog (2013) 4.05

A database of locus-specific databases. Nat Genet (2007) 3.83

Effect of residency duty-hour limits: views of key clinical faculty. Arch Intern Med (2007) 3.58

Stability of the latent reservoir for HIV-1 in patients receiving valproic acid. J Infect Dis (2007) 3.39

Genotypic analysis of HIV-1 drug resistance at the limit of detection: virus production without evolution in treated adults with undetectable HIV loads. J Infect Dis (2004) 3.30

Dose-response curve slope sets class-specific limits on inhibitory potential of anti-HIV drugs. Nat Med (2008) 3.28

Novel loci for adiponectin levels and their influence on type 2 diabetes and metabolic traits: a multi-ethnic meta-analysis of 45,891 individuals. PLoS Genet (2012) 3.21

The HBV drug entecavir - effects on HIV-1 replication and resistance. N Engl J Med (2007) 3.20

Genome-wide association study identifies loci influencing concentrations of liver enzymes in plasma. Nat Genet (2011) 3.18

Resting CD4+ T cells from human immunodeficiency virus type 1 (HIV-1)-infected individuals carry integrated HIV-1 genomes within actively transcribed host genes. J Virol (2004) 3.17

Novel single-cell-level phenotypic assay for residual drug susceptibility and reduced replication capacity of drug-resistant human immunodeficiency virus type 1. J Virol (2004) 3.13

Abnormalities of the large ribosomal subunit protein, Rpl35a, in Diamond-Blackfan anemia. Blood (2008) 3.05

Enhanced culture assay for detection and quantitation of latently infected, resting CD4+ T-cells carrying replication-competent virus in HIV-1-infected individuals. Methods Mol Biol (2005) 2.99

Common variants associated with plasma triglycerides and risk for coronary artery disease. Nat Genet (2013) 2.92

Neutralizing antibodies do not mediate suppression of human immunodeficiency virus type 1 in elite suppressors or selection of plasma virus variants in patients on highly active antiretroviral therapy. J Virol (2006) 2.91

Molecular characterization of preintegration latency in human immunodeficiency virus type 1 infection. J Virol (2002) 2.89

Analysis of human immunodeficiency virus type 1 gene expression in latently infected resting CD4+ T lymphocytes in vivo. J Virol (2003) 2.78

Small-molecule screening using a human primary cell model of HIV latency identifies compounds that reverse latency without cellular activation. J Clin Invest (2009) 2.75

Experimental approaches to the study of HIV-1 latency. Nat Rev Microbiol (2007) 2.71

The multifactorial nature of HIV-1 latency. Trends Mol Med (2004) 2.68

G-->A hypermutation in protease and reverse transcriptase regions of human immunodeficiency virus type 1 residing in resting CD4+ T cells in vivo. J Virol (2005) 2.61

Genome-wide analyses of steroid- and radiation-triggered programmed cell death in Drosophila. Curr Biol (2003) 2.59

Redefining the viral reservoirs that prevent HIV-1 eradication. Immunity (2012) 2.56

Kinetics of human immunodeficiency virus type 1 decay following entry into resting CD4+ T cells. J Virol (2005) 2.55

Exome array analysis identifies new loci and low-frequency variants influencing insulin processing and secretion. Nat Genet (2012) 2.55

Intrinsic stability of episomal circles formed during human immunodeficiency virus type 1 replication. J Virol (2002) 2.32

The centrosome in human genetic disease. Nat Rev Genet (2005) 2.25

Disulfiram reactivates latent HIV-1 in a Bcl-2-transduced primary CD4+ T cell model without inducing global T cell activation. J Virol (2011) 2.18

A simian immunodeficiency virus-infected macaque model to study viral reservoirs that persist during highly active antiretroviral therapy. J Virol (2009) 2.10

Orientation-dependent regulation of integrated HIV-1 expression by host gene transcriptional readthrough. Cell Host Microbe (2008) 2.08

Nuclear retention of multiply spliced HIV-1 RNA in resting CD4+ T cells. PLoS Pathog (2006) 2.08

Marked intraindividual variability in antiretroviral concentrations may limit the utility of therapeutic drug monitoring. Clin Infect Dis (2006) 2.06

Promotion criteria for clinician-educators. J Gen Intern Med (2003) 2.03

Rapid quantification of the latent reservoir for HIV-1 using a viral outgrowth assay. PLoS Pathog (2013) 2.02

Identification of nevirapine-resistant HIV-1 in the latent reservoir after single-dose nevirapine to prevent mother-to-child transmission of HIV-1. J Infect Dis (2009) 1.93

Viral reservoirs, residual viremia, and the potential of highly active antiretroviral therapy to eradicate HIV infection. J Allergy Clin Immunol (2008) 1.91

Resting CD4+ T lymphocytes but not thymocytes provide a latent viral reservoir in a simian immunodeficiency virus-Macaca nemestrina model of human immunodeficiency virus type 1-infected patients on highly active antiretroviral therapy. J Virol (2003) 1.89

Analysis of human immunodeficiency virus type 1 viremia and provirus in resting CD4+ T cells reveals a novel source of residual viremia in patients on antiretroviral therapy. J Virol (2009) 1.89

Persistence of wild-type virus and lack of temporal structure in the latent reservoir for human immunodeficiency virus type 1 in pediatric patients with extensive antiretroviral exposure. J Virol (2002) 1.88

BET bromodomain-targeting compounds reactivate HIV from latency via a Tat-independent mechanism. Cell Cycle (2012) 1.88

A long-term latent reservoir for HIV-1: discovery and clinical implications. J Antimicrob Chemother (2004) 1.87

General framework for meta-analysis of rare variants in sequencing association studies. Am J Hum Genet (2013) 1.86

Continued production of drug-sensitive human immunodeficiency virus type 1 in children on combination antiretroviral therapy who have undetectable viral loads. J Virol (2004) 1.85

Latency in human immunodeficiency virus type 1 infection: no easy answers. J Virol (2003) 1.83

The antiherpetic drug acyclovir inhibits HIV replication and selects the V75I reverse transcriptase multidrug resistance mutation. J Biol Chem (2008) 1.83

Preservation of FoxP3+ regulatory T cells in the peripheral blood of human immunodeficiency virus type 1-infected elite suppressors correlates with low CD4+ T-cell activation. J Virol (2008) 1.82

Limits on replenishment of the resting CD4+ T cell reservoir for HIV in patients on HAART. PLoS Pathog (2007) 1.81

Mouse ES cell-derived cardiac precursor cells are multipotent and facilitate identification of novel cardiac genes. J Clin Invest (2008) 1.80

A comparison of viral loads between HIV-1-infected elite suppressors and individuals who receive suppressive highly active antiretroviral therapy. Clin Infect Dis (2008) 1.76

Ex vivo analysis identifies effective HIV-1 latency-reversing drug combinations. J Clin Invest (2015) 1.76

Decay dynamics of HIV-1 depend on the inhibited stages of the viral life cycle. Proc Natl Acad Sci U S A (2008) 1.72

Minocycline attenuates HIV infection and reactivation by suppressing cellular activation in human CD4+ T cells. J Infect Dis (2010) 1.70

A quantitative basis for antiretroviral therapy for HIV-1 infection. Nat Med (2012) 1.68

Control of HIV-1 in elite suppressors despite ongoing replication and evolution in plasma virus. J Virol (2010) 1.66

Transmission of human immunodeficiency virus type 1 from a patient who developed AIDS to an elite suppressor. J Virol (2008) 1.66

Analysis of human immunodeficiency virus type 1 transcriptional elongation in resting CD4+ T cells in vivo. J Virol (2004) 1.64

The role of protective HCP5 and HLA-C associated polymorphisms in the control of HIV-1 replication in a subset of elite suppressors. AIDS (2008) 1.63

HIV-1 viral load blips are of limited clinical significance. J Antimicrob Chemother (2006) 1.63

Multi-step inhibition explains HIV-1 protease inhibitor pharmacodynamics and resistance. J Clin Invest (2013) 1.62

Antiretroviral dynamics determines HIV evolution and predicts therapy outcome. Nat Med (2012) 1.61

Sharing data between LSDBs and central repositories. Hum Mutat (2009) 1.57

Medical student and faculty perceptions of volunteer outpatients versus simulated patients in communication skills training. Acad Med (2011) 1.53

Prevalence of complementary and alternative medicine use among HIV patients for perceived lipodystrophy. J Altern Complement Med (2006) 1.51

The anti-HIV activity of entecavir: a multicentre evaluation of lamivudine-experienced and lamivudine-naive patients. AIDS (2008) 1.50

Elite suppressor-derived HIV-1 envelope glycoproteins exhibit reduced entry efficiency and kinetics. PLoS Pathog (2009) 1.49

Population bottlenecks as a potential major shaping force of human genome architecture. PLoS Genet (2007) 1.47

Targeting HIV latency: pharmacologic strategies toward eradication. Drug Discov Today (2012) 1.47

Role of APOBEC3G/F-mediated hypermutation in the control of human immunodeficiency virus type 1 in elite suppressors. J Virol (2007) 1.47

Severe depletion of CD4+ CD25+ regulatory T cells from the intestinal lamina propria but not peripheral blood or lymph nodes during acute simian immunodeficiency virus infection. J Virol (2007) 1.47

A pilot study assessing the safety and latency-reversing activity of disulfiram in HIV-1-infected adults on antiretroviral therapy. Clin Infect Dis (2013) 1.46

No evidence for decay of the latent reservoir in HIV-1-infected patients receiving intensive enfuvirtide-containing antiretroviral therapy. J Infect Dis (2010) 1.45

HIV latency and integration site placement in five cell-based models. Retrovirology (2013) 1.42

Can antiretroviral therapy ever be stopped? An update. AIDS Read (2004) 1.42

Evolution of HIV-1 in an HLA-B*57-positive patient during virologic escape. J Infect Dis (2007) 1.41

General internists' beliefs, behaviors, and perceived barriers to routine HIV screening in primary care. AIDS Educ Prev (2011) 1.38